Cherry, Christopher
Andorko, James I.
Krishnan, Kavita
Mejías, Joscelyn C.
Nguyen, Helen Hieu
Stivers, Katlin B.
Gray-Gaillard, Elise F.
Ruta, Anna
Han, Jin
Hamada, Naomi
Hamada, Masakazu
Sturmlechner, Ines
Trewartha, Shawn
Michel, John H.
Davenport Huyer, Locke
Wolf, Matthew T.
Tam, Ada J.
Peña, Alexis N.
Keerthivasan, Shilpa
Le Saux, Claude Jordan
Fertig, Elana J.
Baker, Darren J.
Housseau, Franck
van Deursen, Jan M.
Pardoll, Drew M.
Elisseeff, Jennifer H. http://orcid.org/0000-0002-5066-1996
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-17-1-0627, W81XWH-14-1-0285)
Office of Strategic Coordination (DP1AR076959)
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Johns Hopkins University
Bristol-Myers Squibb
National Cancer Institute (U01CA253403)
Foundation for the National Institutes of Health (R01 AG057493, 1T32AG058527-01, 5T32CA153952-08)
National Science Foundation (DGE-1746891, DGE-1746891)
Article History
Received: 1 February 2023
Accepted: 26 March 2023
First Online: 20 April 2023
Declarations
:
: J.H.E. holds equity in Unity Biotechnology and Aegeria Soft Tissue and is an advisor for Tessera Therapeutics, HapInScience, and Font Bio. D.M.P. is consultant at Aduro Biotech, Amgen, Astra Zeneca, Bayer, Compugen, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Immunomic, Janssen, Merck, and Rock Springs Capital. D.M.P. holds equity in Aduro Biotech, DNAtrix, Ervaxx, Five Prime therapeutics, Immunomic, Potenza, and Trieza Therapeutics. D.M.P. is a member of the scientific advisory board for Bristol Myers Squibb, Camden Nexus II, Five Prime Therapeutics, and WindMil. D.M.P. is a member of the board of directors in Dracen Pharmaceuticals. C.C. is the founder and owner of C M Cherry Consulting, LLC. E.J.F. is a member of the scientific advisory board for Resistance Bio and is a consultant for Merck and Mestag Therapeutics. J.M.v.D. is a co-founder of and holds equity in Unity Biotechnology and Cavalry Biosciences. D.J.B. is a shareholder and co-inventor on patent applications licensed to or filed by Unity Biotechnology, a company developing senolytic medicines, including small molecules that selectively eliminate senescent cells. Research in his laboratory has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.